Table 3 Sequence types (STs) associated with significant increases in Relative Risk of being an hVISA compared to the rest of the cohort (two-sided χ2 test)

From: Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold

ST

Non-hVISA

hVISA

Relative Risk

CI

p value

ST239

89

1

0.04537

0.007959–0.2536

0.0001

ST72

4

14

11.7

4.093–33.47

0.0001

ST8

95

7

0.2905

0.1385–0.5985

0.0004

ST30

50

2

6.568

1.799–24.41

0.0019

ST34

199

89

1.404

1.135–1.724

0.002

ST5

1

3

13.63

1.961–94.67

0.003

ST188

51

21

0.5583

0.3500–0.9031

0.0173

Back to article page